Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthBHC +0.82%58 Debt-to-EBITDA is -7.91 as of Mar. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.92 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Bausch Health ranks worse than 92.9% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bausch Health's Debt-to-EBITDA or its related term are showing as below:
BHC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 6.56 Med: 10.02 Max: 69.44
Current: 10.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of Bausch Health was 69.44. The lowest was 6.56. And the median was 10.02.
BHC's Debt-to-EBITDA is ranked worse than 92.9% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs BHC: 10.71
Bausch Health (NYSE:BHC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bausch Health Debt-to-EBITDA Related Terms
Bausch Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bausch Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bausch Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Bausch Health (BHC) has a Debt-to-EBITDA of -7.91 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bausch Health. Over the past decade, Bausch Health's Debt-to-EBITDA has ranged from 6.56 to 69.44. According to the industry distribution chart, Bausch Health ranks #641 out of 690 companies in the Drug Manufacturers industry, placing it in the top 92.9%.
Is Bausch Health's Debt-to-EBITDA too high?
Bausch Health's current Debt-to-EBITDA is -7.91. Over the past 10 years, this metric has ranged from a low of 6.56 to a high of 69.44. Based on the distribution chart, Bausch Health ranks #641 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #641 out of 690 companies for Debt-to-EBITDA. This places Bausch Health in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Historically, Bausch Health's own Debt-to-EBITDA has ranged from 6.56 to 69.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bausch Health. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current Debt-to-EBITDA is -7.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.92, compared to a current price of $4.93 — trading 37.8% below its estimated fair value. The current Debt-to-EBITDA is -7.91. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bausch Health (BHC), the current Debt-to-EBITDA is -7.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $4.93 is trading 37.8% below its estimated GF Value™ of $7.92.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for BHC:
Debt-to-EBITDA: -7.91
GF Value™: $7.92 vs. price of $4.93 (37.8% below fair value)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score
Get the complete analysis for BHC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
